RedHill Biopharma Advances Opaganib for GI-ARS Treatment

RedHill Biopharma (RDHL) has released an update.

RedHill Biopharma has reported promising results for its drug Opaganib in treating gastrointestinal acute radiation syndrome (GI-ARS), a condition with no current approved therapies. The drug, which is part of a U.S. government-funded development initiative, shows potential as a key medical countermeasure during nuclear or radiological emergencies. Ongoing discussions with the National Institutes of Health aim to advance Opaganib’s development through the FDA’s Animal Rule pathway.

For further insights into RDHL stock, check out TipRanks’ Stock Analysis page.